Wissenschaft und Forschung

Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sektionen
Arbeitsgruppe Epidemiologie der Herzinsuffizienz
Sie sind hier: Startseite / Kardiologie / Wissenschaft und Forschung / Arbeitsgruppe Epidemiologie der Herzinsuffizienz

Arbeitsgruppe Epidemiologie der Herzinsuffizienz

Mitglieder

Portrait Dr Pfister

Priv.-Doz. Dr. med. Roman Pfister
[Email protection active, please enable JavaScript.]

 

 

 

 

 

 

Portrait Dr Michels

Priv.-Doz. Dr. med. Guido Michels
[Email protection active, please enable JavaScript.]

 

 

 

 

 

Kontakt
Klinik III für Innere Medizin
Herzzentrum, EG Raum 122
Universitätsklinik Köln
Kerpener Str. 62
50937 Köln
Telefon: +49 221 478-32413
E-Mail: [Email protection active, please enable JavaScript.]

Forschungsschwerpunkt
Die Herzinsuffizienz stellt die Endstrecke verschiedener kardiovaskulärer Erkrankungen dar und nimmt epidemische Ausmaße an, was zu einer enormen medizinischen und gesundheitsökonomischen Belastung führt. Ziel unserer Forschung ist es, die Pathophysiologie der Entwicklung und Progression der Herzinsuffizienz besser zu verstehen und damit die Möglichkeit für neue und gezielte Interventionen zu schaffen. Dazu werden „Lifestyle“-Faktoren, Biomarker und genetische Faktoren und deren Assoziation mit Herzinsuffizienzentwicklung und Prognose untersucht.

Kollaborationen

Ausgewählte Publikationen

Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Low Bone Mineral Density Predicts Incident Heart Failure in Men and Women: The EPIC (European Prospective Investigation Into Cancer and Nutrition)-Norfolk Prospective Study. JACC Heart Fail. 2014 Aug;2(4):380-9.

Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Estimated urinary sodium excretion and risk of heart failure in men and women in the EPIC-Norfolk study. Eur J Heart Fail. 2014 Jan 20. doi: 10.1002/ejhf.56. [Epub ahead of print]

Pfister R, Michels G, Wilfried J, Luben R, Wareham NJ, Khaw KT. Does ICD-10 hospital discharge code I50 identify people with heart failure? A validation study within the EPIC-Norfolk study. Int J Cardiol. 2013 Oct 9;168(4):4413-4.

Emans ME, Gaillard CA, Pfister R, Tanck MW, Boekholdt SM, Wareham NJ, Khaw KT. Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC-Norfolk study. Int J Cardiol. 2013 Oct 9;168(4):3550-5.

Pfister R, Luben RN, Khaw KT, Wareham NJ. Common genetic variants of the natriuretic peptide gene locus are not associated with heart failure risk in participants in the EPIC-Norfolk study. Eur J Heart Fail. 2013 Jun;15(6):624-627.

Pfister R, Cairns R, Erdmann E, Schneider CA. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. Int J Cardiol. 2013 Jan 10;162(2):112-6.

Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur J Heart Fail. 2012 Oct;14(10):1163-70.

Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012 Mar 31;379(9822):1214-24.

Pfister R, Hagemeister J, Esser S, Hellmich M, Erdmann E, Schneider CA. NT-pro-BNP for diagnostic and prognostic evaluation in patients hospitalized for syncope. Int J Cardiol. 2012 Mar 8;155(2):268-72.

Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. Eur Heart J. 2012 Feb;33(4): 523-530.

Pfister R, Michels G, Cairns R, Schneider CA, Erdmann E. Incidence of new onset bundle branch block and atrial fibrillation in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. Int J Cardiol. 2011 Dec 1;153(2):233-4.

Pfister R, Sharp S, Luben R, Welsh P, Barroso I, et al. Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population Studies. PLoS Med 2011;8(10): e1001112. doi:10.1371/journal.pmed.1001112

Pfister R, Barnes D, Luben R, Forouhi NG, Bochud M, Khaw KT, Wareham NJ, Langenberg C. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia. 2011 Oct;54(10):2561-9.

Pfister R, Cairns R, Erdmann E, Schneider CA; on behalf of the PROactive investigators. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study. Diabet Med. 2011 Oct;28(10):1206-1212.

Pfister R, Barnes D, Luben RN, Khaw KT, Wareham NJ, Langenberg C. Individual and cumulative effect of type 2 diabetes genetic susceptibility variants on risk of coronary heart disease. Diabetologia. 2011 Sep;54(9):2283-7.

Pfister R, Sharp SJ, Luben R, Khaw KT, Wareham NJ. No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia. 2011 Aug;54(8):2025-32.

Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. Am Heart J. 2011 Aug;162(2):246-53.

Pfister R, Müller-Ehmsen J, Hagemeister J, Hellmich M, Erdmann E, Schneider CA. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure. Int Med J. 2011 Jun;41(6):467-72.

Pfister R, Cairns R, Erdmann E, Schneider CA. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. Int J Cardiol. 2011 May 31. [Epub ahead of print]

Pfister R, Erdmann E, Schneider CA. Association and prognostic impact of heart rate and micro- albuminuria in patients with type 2 diabetes and cardiovascular disease: Results from the PROactive trial. J Atheroscler Thromb. 2011 Jan 27;18(1):65-71.

Pfister R, Strack N, Wielckens K, Malchau G, Erdmann E, Schneider CA.The relationship and prognostic impact of low-T3 syndrome and NT-pro-BNP in cardiovascular patients. Int J Cardiol. 2010 Oct 8;144(2):187-90.

Pfister R, Wahlers T, Baer FM, Scherner M, Strauch J, Erdmann E. Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement. Clin Res Cardiol 2010. May;99(5):301-7.

Pfister R, Diedrichs H, Larbig R, Erdmann E, Schneider CA. NT-pro-BNP for differential diagnosis in patients with syncope. Int J Cardiol. 2009 Mar 20;133(1):51-4.

Pfister R, Tan D, Thekkanal J, Hellmich M, Schneider CA. Predictors of elevated NT-pro-BNP in cardiovascular patients without acute heart failure. Int J Cardiol. 2009 Jan 9;131(2):277-80.

Pfister R, Diedrichs H, Schiedermair A, Rosenkranz S, Hellmich M, Erdmann E, Schneider CA. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail. 2008 Mar;10(3):315-20.

Pfister R, Tan D, Thekkanal J, Hellmich M, Erdmann E, Schneider CA. NT-pro-BNP measured at discharge predicts outcome in multimorbid diabetic inpatients with a broad spectrum of cardiovascular disease. Acta Diabetol. 2007 Jul;44(2):91-7.

Pfister R, Tan D, Thekkanal J, Hellmich M, Schneider CA. NT-pro-BNP is associated with long-term outcome in a heterogeneous sample of cardiac inpatients. Eur J Intern Med. 2007 May;18(3):215-20.

Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004 Jun;6(3):289-93.